NEW YORK, NY / ACCESSWIRE / December 9, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

ADTRAN, Inc. (NASDAQ:ADTN)
Class Period: February 28, 2019 to October 9, 2019
Lead Plaintiff Deadline: December 16, 2019

The complaint alleges that throughout the class period ADTRAN, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) there were material weaknesses in the Company's internal control over financial reporting; (2) as a result, certain E&O reserves had been improperly reported; (3) as a result, the Company's financial results for certain periods were misstated; (4) there would be a pause in shipments to the Company's Latin American customer; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in ADTN: http://www.kleinstocklaw.com/pslra-1/adtran-inc-loss-submission-form?id=4786&from=1

Domo, Inc. (NASDAQ:DOMO)
Class Period: shareholders who acquired: (a) Domo common stock pursuant and/or traceable to the Company's initial public offering commenced on or around June 29, 2018; or (b) Domo securities between June 28, 2018 and September 5, 2019, both dates inclusive.
Lead Plaintiff Deadline: December 16, 2019

The complaint alleges Domo, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Domo was experiencing weakness in its enterprise and international businesses; (ii) Domo's billings growth had dramatically slowed; (iii) all of the foregoing was reasonably likely to have a material negative impact on the Company's financial results; and (iv) as a result, the Offering Documents were materially false and/or misleading and failed to state information required to be stated therein and the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in DOMO: http://www.kleinstocklaw.com/pslra-1/domo-inc-loss-submission-form?id=4786&from=1

Yunji Inc. (NASDAQ:YJ)
Class Period: on behalf of shareholders who purchased or otherwise acquired Yunji American Depositary Shares pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's May 2019 initial public offering.
Lead Plaintiff Deadline: January 13, 2020

During the class period, Yunji Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company was shifting certain of its sales to its marketplace platform; (2) this supply chain restructuring was likely to disrupt Yunji's relationships with suppliers; (3) this supply chain restructuring was likely to have an adverse impact on the Company's financial results; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in YJ: http://www.kleinstocklaw.com/pslra-1/yunji-inc-loss-submission-form?id=4786&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 569590

NEW YORK, NY / ACCESSWIRE / December 9, 2019 / The following statement is being issued by Levi & Korsinsky, LLP:

Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies.

Audentes Therapeutics, Inc. (NASDAQ:BOLD)
Merger Announcement: December 2, 2019
Transaction Details: Under the terms of the transaction, Astellas will acquire Audentes at a price of $60.00 per share in cash.

To learn more about the BOLD investigation and your rights, go to: https://www.zlk.com/mna/audentes-therapeutics-inc

Instructure, Inc. (NYSE:INST)
Merger Announcement: December 4, 2019
Transaction Details: Under the terms of the transaction, Instructure stockholders will receive $47.60 in cash per share.

To learn more about the INST investigation and your rights, go to: https://www.zlk.com/mna/instructure-inc

Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
jlevi@levikorsinsky.com
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 569583

NEW YORK, NY / ACCESSWIRE / December 9, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine your eligibility and get free access to our shareholder support tools that provide you with case updates, automated loss calculations and claims recovery assistance, please contact the firm via the links below. There will be no cost or obligation to you.

Infosys Limited (NYSE:INFY)

INFY Lawsuit on behalf of: investors who purchased July 7, 2018 – October 20, 2019
Lead Plaintiff Deadline : December 23, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/infosys-limited-loss-form?prid=4784&wire=1

According to the filed complaint, during the class period, Infosys Limited made materially false and/or misleading statements and/or failed to disclose that: (1) the Company improperly recognized revenues to inflate short-term profits; (2) Chief Executive Officer Salil Parekh bypassed reviews and approvals for large deals to avoid accounting scrutiny; (3) management pressured the Company's finance team to hide information from auditors and the Company's Board of Directors; and (4) as a result of the aforementioned misconduct, Defendants' statements about Infosys's business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.

Baxter International Inc. (NYSE:BAX)

BAX Lawsuit on behalf of: investors who purchased February 21, 2019 – October 23, 2019
Lead Plaintiff Deadline : January 24, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/baxter-international-inc-loss-form?prid=4784&wire=1

According to the filed complaint, during the class period, Baxter International Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) certain intra-Company transactions, undertaken for the purpose of generating foreign exchange gains and losses, used foreign exchange rate conventions that were not in accordance with GAAP and enabled intra-Company transactions to be undertaken after the related exchange rates were already known; (2) the Company lacked effective internal control over financial reporting; (3) as a result, the Company's financial statements were misstated and would likely require correction or amendment; (4) due to the Company's internal investigation, Baxter would not be able to file its quarterly report for the period ending September 30, 2019, with the SEC on Form 10-Q in a timely manner; and (5) as a result of the foregoing, Defendants' statements about the Company's business and operations lacked a reasonable basis.

Merit Medical Systems, Inc. (NASDAQ:MMSI)

MMSI Lawsuit on behalf of: investors who purchased February 26, 2019 – October 30, 2019
Lead Plaintiff Deadline : February 3, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/merit-medical-systems-inc-loss-form?prid=4784&wire=1

According to the filed complaint, during the class period, Merit Medical Systems, Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) the integrations of acquired companies Cianna Medical, Inc. and Vascular Insights, LLC, including their products, sales people, and R&D facilities, had caused operational disruptions and reduced sales and were months behind schedule; (b) sales of acquired company products had slowed substantially due to pre-acquisition pipeline fill, in particular for Vascular Insights products which, as late as July 2019, had zero orders during FY19; and (c) in light of the foregoing, the Company's reported financial guidance for FY19 and FY20 was made without a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 569588

NEW YORK, NY / ACCESSWIRE / December 9, 2019 / The following statement is being issued by Levi & Korsinsky, LLP:

Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies.

The Medicines Company (NASDAQ:MDCO)
Merger Announcement: November 24, 2019
Transaction Details: Under the terms of the transaction, Novartis will acquire The Medicines Company for $85 per share in an all-cash transaction.

To learn more about the MDCO investigation and your rights, go to: https://www.zlk.com/mna/the-medicines-company

Tiffany & Co. (NYSE:TIF)
Merger Announcement: November 25, 2019
Transaction Details: Under the terms of the transaction, LVMH will acquire Tiffany for $135 per share in cash.

To learn more about the TIF investigation and your rights, go to: https://www.zlk.com/mna/tiffany-co

Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
jlevi@levikorsinsky.com
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 569581

NEW YORK, NY / ACCESSWIRE / December 9, 2019 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased ArQule, Inc. ("ArQule" or the "Company") (NASDAQ:ARQL) stock prior to December 9, 2019.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of ArQule to Merck & Co., Inc. ("Merck") (NYSE: MRK). Under the terms of the transaction, ArQule shareholders will receive $20 per share in cash. To learn more about the action and your rights, go to:

https://www.zlk.com/mna/arqule-inc

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

The ArQule merger investigation concerns whether the Board of ArQule breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction and whether Merck is underpaying for ArQule shares, thus unlawfully harming ArQule shareholders.

Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 569579

TORONTO, ON / ACCESSWIRE / December 9, 2019 / Toronto based CO2 GRO Inc. ("GROW") (TSX-V:GROW, OTCQB:BLONF, Frankfurt: 4021) is pleased to announce it has signed a Commercial Demonstration Proposal ("Demo") with a Canadian Cannabis Producer ("Client"). The Demo will run from mid-December 2019 to June 2020.

The objectives of this Demo are: greater yield while optimizing resources including faster cannabis plant growth for more harvests, more bud and overall plant biomass, and more cannabinoid production. Upon successful completion of the Demo, GROW anticipates installing a complete CO2 Delivery Solutions system throughout the Client's facility in Canada and potentially at the Client's international facility.

The Client's unique proprietary cultivation method creates a virtually odorless cannabis product that would be the first of its kind in the marketplace.

According to John Archibald, GROW's CEO "With now hundreds of Health Canada approved cannabis producers, we look forward to more Canadian demonstrations of our CO2 Delivery Solutions technology with cannabis producers to showcase its numerous benefits."

Visit www.co2delivery.ca for more information on CO2 Delivery Solutions or watch this video.

About CO2 GRO Inc.

GROW's mission is to accelerate the growth of all value plants safely, effectively and profitably using our patent protected advanced CO2 Delivery Solutions. It is a commercially proven technology that is easily adopted into greenhouses, indoor and outdoor grow operations.

GROW's target markets are the 50 billion square feet of global greenhouse space (USDA) and the 4.62 billion acres of global cropland (USGS). While indoor gassing of CO2 to enhance crop yields has been practiced for decades, 85% of the world's greenhouses cannot use CO2 gassing economically due mostly to heat ventilation which causes the CO2 gas to escape. Outdoor growers cannot gas CO2 into the atmosphere to the ideal levels required of up to 1500 ppm.

GROW's CO2 Delivery Solutions naturally and safely dissolves CO2 gas into water creating an aqueous CO2 solution which is then misted directly on plant leaves. GROW has demonstrated improving crop yields by up to 30% with up to 30% faster growth. The CO2 solution's micro droplets create an aqueous film around the entire leaf surface, isolating the leaf from the atmosphere. This creates a diffusion gradient favoring CO2 transport into the leaf and other gases out of the leaf. Increased carbon availability enhances photosynthesis resulting in faster and larger plant growth. CO2 Delivery Solutions has been demonstrated on crops including cannabis, lettuce, kale, microgreens, peppers, flowers and medical tobacco. Growers everywhere can now supplement CO2 to their crops using CO2 Delivery Solutions, increasing plant yields and profits.

Forward-Looking Statements This news release may contain forward-looking statements that are based on CO2 GRO's expectations, estimates and projections regarding its business and the economic environment in which it operates. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. Statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information, please visit www.co2gro.ca or contact Sam Kanes, VP Communications at 416-315-7477.

SOURCE: Co2 Gro Inc.

ReleaseID: 569568

LOS ANGELES, CA / ACCESSWIRE / December 9, 2019 / Private Lending Firm MCG, is proud to announce the purchase and finance of a hotel portfolio. This deal, worth $1.17 Billion, consists of nine luxury franchise hotels.

"In our ten years of business, this is the second largest deal we have financed to date. I am glad we were able to get this done for our clients" said Stan Bril, founder and CEO of MCG.

For more information about MCG visit: http://www.mcgloan.com/.

About MCG

MCG is a commercial lender that funds construction, commercial mortgages, bridge financing, and business financing products. MCG is dedicated to helping those in need of real estate loans to get the assistance they need. Led by founder and CEO, Stan Bril, the firm excels from their founder's experience in finance and real estate. Through Bril's vision, the company has focused on providing structured, non-conforming loans that allow investors to finish projects and keep up with the demands of their business. With their innovative lending products, the company has brought a new sense of creativity to the lending market that helps facilitate growth and profitability. This private commercial lending institution has been providing quality loans since its inception in 2009.

CONTACT:

Stan Bril
stanbril@hotmail.com

SOURCE: Stan Bril

ReleaseID: 569565

WILMINGTON, DE / ACCESSWIRE / December 9, 2019 / Rigrodsky & Long, P.A.:

Do you own shares of Synthorx, Inc. (NASDAQ GS:THOR)? 
Did you purchase any of your shares prior to December 9, 2019?
Do you think the proposed buyout is fair?
Do you want to discuss your rights?

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors Synthorx, Inc. ("Synthorx" or the "Company") (NASDAQ GS: THOR) regarding possible breaches of fiduciary duties and other violations of law related to the Company's entry into an agreement to be acquired by Sanofi (NASDAQ GS: SNY) in a transaction valued at approximately $2.5 billion. Under the terms of the agreement, shareholders of Synthorx will receive $68.00 in cash for each share of Synthorx they own.

If you own common stock of Synthorx and purchased any shares before December 9, 2019, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D. Rigrodsky or Gina M. Serra toll-free at (888) 969-4242, by e-mail at info@rl-legal.com, or at https://www.rigrodskylong.com/offices-contact.

Rigrodsky & Long, P.A., with offices in Delaware, New York, and California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.

Attorney advertising. Prior results do not guarantee a similar outcome.

CONTACT: 

Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242
(302) 295-5310
Fax: (302) 654-7530
info@rl-legal.com 
http://www.rigrodskylong.com

SOURCE: Rigrodsky & Long, P.A.

ReleaseID: 569564

WILMINGTON, DE / ACCESSWIRE / December 9, 2019 / Rigrodsky & Long, P.A.:

Do you own shares of Texas Capital Bancshares, Inc. (NASDAQ GS:TCBI)? 
Did you purchase any of your shares prior to December 9, 2019?
Do you think the proposed merger is fair?
Do you want to discuss your rights?

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors Texas Capital Bancshares, Inc. ("Texas Capital" or the "Company") (NASDAQ GS: TCBI) regarding possible breaches of fiduciary duties and other violations of law related to the Company's entry into an agreement to be acquired by Independent Bank Group, Inc. ("Independent Bank") (NASDAQ GS: IBTX). Under the terms of the agreement, shareholders of Texas Capital will receive 1.0311 shares of Independent Bank for each share of Texas Capital they own. Upon completion of the transaction, shareholders of Texas Capital will own approximately 55% of the combined company and Independent Bank shareholders will own approximately 45%.

If you own common stock of Texas Capital and purchased any shares before December 9, 2019, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D. Rigrodsky or Gina M. Serra toll-free at (888) 969-4242, by e-mail at info@rl-legal.com, or at https://www.rigrodskylong.com/offices-contact.

Rigrodsky & Long, P.A., with offices in Delaware, New York, and California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.

Attorney advertising. Prior results do not guarantee a similar outcome.

CONTACT: 

Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242
(302) 295-5310
Fax: (302) 654-7530
info@rl-legal.com 
http://www.rigrodskylong.com

SOURCE: Rigrodsky & Long, P.A.

ReleaseID: 569559

WILMINGTON, DE / ACCESSWIRE / December 9, 2019 / Rigrodsky & Long, P.A.:

Do you own shares of ArQule, Inc. (NASDAQ GM:ARQL)?

Did you purchase any of your shares prior to December 9, 2019?
Do you think the proposed buyout is fair?
Do you want to discuss your rights?

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors ArQule, Inc. ("ArQule" or the "Company") (NASDAQ GM: ARQL) regarding possible breaches of fiduciary duties and other violations of law related to the Company's entry into an agreement to be acquired by an affiliate of Merck & Co., Inc. (NYSE: MRK) in a transaction valued at approximately $2.7 billion. Under the terms of the agreement, shareholders of ArQule will receive $20.00 in cash for each share of ArQule they own.

If you own common stock of ArQule and purchased any shares before December 9, 2019, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D. Rigrodsky or Gina M. Serra toll-free at (888) 969-4242, by e-mail at info@rl-legal.com, or at https://www.rigrodskylong.com/offices-contact.

Rigrodsky & Long, P.A., with offices in Delaware, New York, and California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.

Attorney advertising. Prior results do not guarantee a similar outcome.

CONTACT:

Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242
(302) 295-5310
Fax: (302) 654-7530|
info@rl-legal.com
http://www.rigrodskylong.com

SOURCE: Rigrodsky & Long, P.A.

ReleaseID: 569555